Immunomodulation with DiNAC-- a new approach to the treatment of atherosclerosis?
Sheila A Doggrell
Index: Expert Opin. Investig. Drugs 11(5) , 717-20, (2002)
Full Text: HTML
Abstract
Not all antioxidants reduce atherosclerosis. This may be because atherosclerosis has an autoimmune, inflammatory pathogenesis. As probucol is both an antioxidant and an immunomodulatory drug, it may be the immunomodulatory effect that underlies its ability to reduce atherosclerosis. N,N-Diacetyl-L-cystine is not an antioxidant but is immunomodulatory. In the Watanabe-heritable hyperlipidaemic rabbit model of familial hypercholesterolaemia, N,N-diacetyl-L-cystine treatment does not lower lipid levels but it does reduce atherosclerosis. Immunomodulation may be a new approach to the treatment of atherosclerosis.
Related Compounds
| Structure | Name/CAS No. | Molecular Formula | Articles |
|---|---|---|---|
 |
N,N'-Diacetyl-L-cystine
CAS:5545-17-5 |
C10H16N2O6S2 |
|
Influence of N,N'-diacetyl-L-cystine on D-galactosamine/lipo...
2004-10-01 [Yao Xue Xue Bao 39(10) , 782-6, (2004)] |
|
The new oral immunomodulating drug DiNAC induces brachial ar...
2008-01-01 [Atherosclerosis 196(1) , 275-82, (2008)] |
|
N,N'-Diacetyl-L-cystine-the disulfide dimer of N-acetylcyste...
1999-03-01 [J. Pharmacol. Exp. Ther. 288(3) , 1174-84, (1999)] |
|
Monitoring of the subtraction process in solid-phase represe...
2001-06-27 [Gene 271(2) , 183-92, (2001)] |
|
[Cysteine in parenteral nutrition: comparative study of N-ac...
1988-04-01 [Infusionstherapie 15(2) , 89-92, (1988)] |